ENGINEERED PROTEINS TO REPAIR OR REGROW DAMAGED HEART MUSCLE CELLS AND TISSUE
Associate Professor Dan Hesselson,
Head of the Centre for Biomedical AI,
Centenary Institute
Sydney, Australia
RESEARCHER PROFILE
Filmed in Sydney, Australia | July 2026
Associate Professor Dan Hesselson leads the Centre for Biomedical AI at the Centenary Institute.
He is an internationally trained research leader in regenerative medicine, focusing on cells and organs affected by heart disease, diabetes and cancer. His work uses insights from the study of basic regenerative processes to identify novel therapeutic targets for these devastating diseases.
His work with zebrafish, which started at University of California San Francisco (UCSF) and was expanded at the Garvan Institute, made significant contributions to our understanding of the molecular mechanisms of regeneration in this highly regenerative model system.
At the Centenary Institute, he is focused on exploiting these breakthroughs in basic science to develop new therapeutic strategies using the power of Directed Evolution to generate potent and highly specific biologic drugs.
His research is investigating new ways to repair the heart and improve outcomes for individuals recovering from heart attacks or living with heart disease, aiming to address a critical gap in cardiac care.
While current treatments can manage symptoms, they cannot restore heart function once muscle cells are lost. This irreversible damage is why heart failure remains a leading cause of death worldwide.
Associate Professor Hesselson’s research aims to address this challenge by developing therapies based on engineered proteins capable of repairing or regrowing damaged heart muscle cells and tissue.
Source: Supplied and adapted from Centenary Institute media release (June 2026)
-
Interventions for improving outcomes of children who are deaf or hard of hearing
Professor Teresa Ching is a Conjoint Professor at NextSense Institute and Macquarie University, and an Honorary Professor at the University of Queensland in Australia. Her current research focuses on devising culturally sensitive practices in early detection and intervention to maximise children’s outcomes. Working with international colleagues, her current research is also directed towards developing global guidelines and recommendations for hearing screening beyond the newborn period, so that all children can benefit from early detection and intervention. The ultimate goal is to attain equity of care and outcomes for all children with hearing difficulties.
-
Drug delivery of targeted therapies for pancreatic cancer, motor neurone disease
Associate Professor Kara Vine-Perrow is a cancer researcher, educator and research leader in the Faculty of Science, Medicine & Health at the University of Wollongong, where she serves as Deputy Director (Community Partnership and Impact) of the Molecular Horizons Research Institute and leads the Targeted Cancer Therapeutics Laboratory. Her research focuses on developing innovative drug delivery technologies, implantable medical devices and RNA-based therapeutics for difficult-to-treat diseases, with a particular emphasis on pancreatic cancer and motor neurone disease.
-
Vaccine effectiveness against infections triggering autoimmune disease
Dr Deborah Burnett is a Scientia Senior Lecturer and Laboratory Head at UNSW, where she leads a multidisciplinary research program spanning mechanistic immunology and translational vaccinology. Her work focuses on understanding how immune responses can protect against challenging infectious threats, including bacterial infections and infections associated with autoimmune disease.
